Benjamin Lockshin, MD, FAAD

Videos

An expert dermatologist evaluates the role of dupilumab in decreasing the clinical burden of severe atopic dermatitis on patients and their caregivers and shares insight on the future outlook of dupilumab in disease management.

Future Directions for Dupilumab in Atopic Dermatitis Management

Benjamin Lockshin, MD, FAAD, reviews key findings from a phase 2 trial evaluating the safety and efficacy of single-dose dupilumab in children with severe atopic dermatitis.

Phase 2 Trial of Single-Dose Dupilumab in Children with Atopic Dermatitis

Benjamin Lockshin, MD, FAAD, comments on the significance of recent expansions of therapeutics options for patients with atopic dermatitis and unmet needs in the field.

Benjamin Lockshin, MD, FAAD

Articles